| 11/01/2019 16:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 10/31/2019 09:00 |
1st Half of Fiscal 2019 Financial Results |
| 10/30/2019 18:40 |
Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc.(Securities Code: 8840) |
| 10/30/2019 13:00 |
1st Half of Fiscal 2019 Financial Results |
| 10/30/2019 13:00 |
Financial Results for the Second Quarter of Fiscal Year 2019(Consolidated) |
| 10/28/2019 15:00 |
Update on the Japanese Association for Infectious Diseases Statement and Revised Guidelines of the Japanese Pediatric Society for the Treatment of Flu |
| 10/18/2019 15:00 |
FDA Approves XOFLUZA(TM) for the Treatment of Acute Uncomplicated Influenza for People at High Risk of Developing Influenza-Related Complications |
| 10/17/2019 10:00 |
U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections |
| 10/16/2019 15:00 |
Shionogi Filed for the Supplemental New Drug Application of XOFLUZA(R) in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection |
| 10/03/2019 09:00 |
Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens |
| 10/02/2019 11:30 |
Congress Presentation on Clinical Study of S-600918, a Drug Candidate for the Treatment of Refractory/Unexplained Chronic Cough |
| 09/30/2019 13:00 |
Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares |
| 09/02/2019 15:00 |
Special Drug Use Survey for XOFLUZA(R) Announced at OPTIONS X |
| 09/02/2019 15:00 |
The Results of Analyses of PA/I38X-substituted Viruses in XOFLUZA(R) Clinical Studies |
| 09/02/2019 15:00 |
Positive Results for XOFLUZATM Global Phase III Study (MINISTONE-2)in Children with Influenza |
| 09/02/2019 15:00 |
Shionogi Announces Post-Exposure Prophylaxis Results for XOFLUZA(R) in PhaseIII Study (BLOCKSTONE) of Influenza Virus Infection in Household Members |
| 08/29/2019 11:30 |
Shionogi Announces XOFLUZA Tablets 20mg for The Treatment of Influenza Types A and B in Patients 12 years of Age and older Approved in Taiwan. |
| 07/29/2019 13:00 |
Financial Results for the First Quarter of Fiscal Year 2019 (Consolidated) |
| 07/29/2019 13:00 |
Financial Results for the First Quarter of Fiscal Year 2019 |
| 07/29/2019 13:00 |
1st Quarter of Fiscal 2019 Financial Results Conference Call |
| 07/22/2019 16:10 |
Shionogi announces out-licensing agreement with AMR Centre on COT-143,a humanized monoclonal antibody targeting the PcrV protein of P. aeruginosa |
| 07/19/2019 09:00 |
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 07/01/2019 15:00 |
Corporate Governance Report 2019 |
| 06/24/2019 11:00 |
Shionogi Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lusutrombopag, a Thrombopoietin Receptor Agonist and Epertinib, an HER2/EG |
| 06/19/2019 15:15 |
SHIONOGI AND FERRER CONCLUDE A CONTRACT FOR THE PROMOTION IN SPAIN OF RIZMOIC(R) (NALDEMEDINE), A THERAPEUTIC AGENT FOR OPIOID-INDUCED CONSTIPATION |
| 06/18/2019 17:00 |
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 06/18/2019 17:00 |
Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019 |
| 06/13/2019 14:00 |
Shionogi Purchases All Outstanding Shares of Pionnier following the Conclusion of their Joint Study |
| 06/04/2019 15:00 |
Shionogi Announces Positive Top-Line Results for XOFLUZA(R) (Baloxavir Marboxil) Phase III Study (BLOCKSTONE) |
| 05/23/2019 08:00 |
Items Disclosed on Internet Concerning Notice of Convocation Annual General Meeting 2019 |
| 05/23/2019 08:00 |
Notice of Convocation Annual General Meeting 2019 |
| 05/22/2019 15:15 |
SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC(R)(NALDEMEDINE) |
| 05/10/2019 09:00 |
FY2018 Financial Results (April 2018 March 2019) |
| 05/09/2019 13:20 |
Financial Results for the year ended March 31,2019 |
| 05/09/2019 13:20 |
FY2018 Financial Results(April 2018-march 2019) |
| 05/09/2019 13:20 |
Financial Results for Fiscal Year 2018 (Consolidated) |
| 04/22/2019 13:00 |
Notice of Revisions to Dividend Forecasts |
| 04/11/2019 15:15 |
SHIONOGI Concludes a Contract for the Commercialization of Rizmoic(R)(naldemedine),in Germany, the UK, and the Netherlands |
| 04/11/2019 08:30 |
Shionogi Announces Licensing of Symproic(R)(naldemedine) to BioDelivery Sciences International Inc. |
| 04/01/2019 15:00 |
Shionogi Announces the Commencement of its Operations of Shionogi Pharma Co., Ltd. |
| 04/01/2019 15:00 |
SHIONOGI ANNOUNCES SUBMISSION OF CEFIDEROCOL MARKETING AUTHORISATION APPLICATION |
| 03/14/2019 10:25 |
presentation material of R&D meeting of FY2018 |
| 03/07/2019 16:00 |
Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets |
| 03/06/2019 15:00 |
FDA Accepts XOFLUZA(TM) (Baloxavir Marboxil) Supplemental New Drug Application |
| 02/28/2019 13:00 |
Shionogi enters into Comprehensive Cooperation Agreement in the Field of Infectious Desease Focused on Malaria with Nagasaki University. |
| 02/20/2019 15:00 |
Notice Regarding Completion of Cancellation of Treasury Shares |
| 01/31/2019 13:00 |
Notice Regarding Changes of Cancellation of Treasury Shares |
| 01/31/2019 13:00 |
3rd Quarter of Fiscal 2018 Financial Results Conference Call |
| 01/31/2019 13:00 |
Financial Results for the Third Quarter of Fiscal Year 2018(Supplement) |
| 01/31/2019 13:00 |
Financial Results for the Third Quarter of Fiscal Year 2018(Consolidated) |
| 01/23/2019 15:00 |
Shionogi Announces Agreements on Collaborative Research with PeptiDream for New Peptide Drug Conjugate(PDC) Discovery |
| 12/21/2018 18:30 |
Coorporate Governance Report |
| 12/21/2018 15:00 |
Notice Regarding the Status and Completion of Acquisition of Own Shares |
| 12/19/2018 08:30 |
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization |
| 12/14/2018 15:00 |
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares |
| 12/06/2018 11:30 |
SHIONOGI Invests in Vast Therapeutics forFuture In-lisence of Nitric Oxide Inhaled Antimicrobial Drug Candidate |
